A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2012
The current study is designed to evaluate the safety and efficacy, including MRI imaging, across a range of VX-509 doses in subjects with active rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs).
Epistemonikos ID: 951e4a561a48b18c50c6cd3a809f9db714c5fe37
First added on: Mar 23, 2022